The role of heat shock protein 60, vascular endothelial growth factor and antiphospholipid antibodies in Behçet disease

British Journal of Dermatology

Volumn 156, Issue 1, 2007, Pages 32-37

  Shaker, O ^a   Ay El Deen, M A ^a   El Hadidi, H ^b   Grace, B D ^b   El Sherif, H ^a   Abdel Halim, A ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b Cairo University   (Egypt)

Author keywords

Antiphospholipid antibodies; Beh et disease; Heat shock protein 60; Vascular endothelial cell growth factor

Indexed keywords

HEAT SHOCK PROTEIN 60; PHOSPHOLIPID ANTIBODY; VASCULOTROPIN;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; BEHCET DISEASE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DOPPLER ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; EYE DISEASE; FEMALE; HUMAN; INFLAMMATORY DISEASE; LYMPHOCYTE PROLIFERATION; MALE; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; T LYMPHOCYTE; THROMBOGENESIS; VASCULITIS; VISUAL DISORDER;

ADOLESCENT; ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; BEHCET SYNDROME; CASE-CONTROL STUDIES; CHAPERONIN 60; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33845527151     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07536.x     Document Type: Article

References (35)

1. Suzuki KM, Suzuki N. Behçet's disease. Clin Exp Med 2004; 4:10-20.
2. Yazici H, Yurdakul S, Hamaryudan V. Behçet's syndrome. Curr Opin Rheumatol 1999; 11:52-7.
3. Kibaroglu A, Eksioglu-Demiralp E, Akoglu T et al. T and NK cell subset changes with microbial extracts and human HSP60-derived peptides in Behçet's disease. Clin Exp Rheumatol 2004; 22 (4 Suppl. 34):S59-63.
4. Ergun T, Ince U, Eksioglu-Demiralp E et al. HSP 60 expression in mucocutaneous lesions of Behçet's disease. J Am Acad Dermatol 2001; 45:904-9.
5. Ranford JC, Henderson B. Chaperonins in disease: mechanisms, models, and treatments. Mol Pathol 2002; 55:209-13.
6. Direskeneli H, Eksioglu-Demiralp E, Yavuz S et al. T cell responses to 60/65 kDa heat shock protein derived peptides in Turkish patients with Behçet's disease. J Rheumatol 2000; 27:708-13.
7. Keyt B, Berleau L, Nguyen H. The carboxy-terminal domain of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 1996; 271:7788-95.
8. Webb NJ, Myers CR, Watson CJ. Activated human neutrophils express vascular endothelial growth factor. Cytokine 1998; 10:254-7.
9. Cekmen M, Evereklioglu C, Er H et al. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behçet's syndrome. Int J Dermatol 2003; 42:870-5.
10. Detmar M, Yeo KT, Nagy JA et al. Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol 1995; 105:44-50.
11. Bang D, Ji HG, Choi YS, Lee S. Absence of lupus anticoagulants in Behçet's disease. Yonsei Med J 1991; 32:326-9.
12. Anonymous. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet 1990; 335:1078-80.
13. Evereklioglu C, Turkoz Y, Er H et al. Increased nitric oxide production in patients with Behçet's disease: is it a new activity marker? J Am Acad Dermatol 2002; 46:50-4.
14. Orem A, Vanizor B, Cimsit G et al. Decreased nitric oxide production in patients with Behçet's disease. Dermatology 1999; 198:33-6.
15. Knapp RG, Miller MC. Clinical Epidemiology and Biostatistics. Malvern, PA: Harwal Publishing Co., 1992.
16. Imamura Y, Kurokawa MS, Yoshikawa H et al. Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behçet's disease. Clin Exp Immunol 2005; 139:371-8.
17. Hu W, Hasan A, Wilson A. Experimental mucosal induction of uveitis with 60-kDa heat shock protein-derived peptide 336-351. Eur J Immunol 1998; 28:2444-55.
18. Direskeneli H, Saruhan-Direskeneli G. The role of heat shock proteins in Behçet's disease. Clin Exp Rheumatol 2003; 21 (4 Suppl. 30):S44-8.
19. Sakane T, Suzuki N, Nagafuchi H. Etiopathology of Behçet's disease: immunological aspects. Yonsei Medical J 1997; 38:350-8.
20. Keyt BA, Berleau LT, Nguyen HV et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 1996; 271:7788-95.
21. Han SW, Kim GW, Seo JS et al. VEGF gene polymorphisms and susceptibility to rheumatoid arthritis. Rheumatology (Oxford) 2004; 43:1173-7.
22. Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanisms in patients with Behçet's syndrome. J Am Coll Cardiol 2001; 37:517-20.
23. Cho M, Hunt TK, Hussain MZ. Hydrogen peroxide stimulates macrophage vascular endothelial growth factor release. Am J Physiol Heart Circ Physiol 2001; 280:H2357-63.
24. Evereklioglu C, Er H, Turkoz Y, Cekmen M. Serum levels of TNFα, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediators Inflamm 2002; 11:87-93.
25. Xiong M, Elson G, Legarda D et al. Production of vascular endothelial growth factor by murine macrophages: regulation by hypoxia, lactate and the inducible nitric oxide synthase pathway. Am J Pathol 1998; 153:587-98.
26. Matsushita K, Yamakuchi M, Morrell CN et al. Vascular endothelial growth factor regulation of Weibel-Palade-body exocytosis. Blood 2005; 105:207-14.
27. Bozoglu E, Dinc A, Erdem H et al. Vascular endothelial growth factor and monocyte chemoattractant protein-1 in Behçet's patients with venous thrombosis. Clin Exp Rheumatol 2005; 23 (4 Suppl. 38):S42-8.
28. Sancak B, Onder M, Oztas MO et al. Nitric oxide levels in Behçet's disease. J Eur Acad Dermatol Venereol 2003; 17:7-9.
29. Hughes JR, Davies JA. Anticardiolipin antibodies in clinical conditions associated with a risk of thrombotic events. Thromb Res 1998; 89:101-6.
30. El-Ageb EM, Al-Maini MH, Al-Shukaily AK et al. Clinical features of Behçet's disease in patients in the Sultanate of Oman; the significance of antiphospholipid antibodies? Rheumatol Int 2002; 21:176-81.
31. Ermakova NA, Alekberova ZS, Nasonov EL et al. Role of antiphospholipid antibodies in occlusion of retinal vessels in various vascular eye diseases. Vestn Oftalmol 2002; 118:29-32 (article in Russian).
32. Kang HJ, Lee YW, Han SH et al. Anticardiolipin and anti-β2- glycoprotein I antibodies in Behçet's disease. J Korean Med Sci 1998; 13:400-4.
33. Tokay S, Direskeneli H, Yurdakul S et al. Anticardiolipin antibodies in Behçet's disease: a reassessment. Rheumatology (Oxford) 2001; 40:192-5.
34. Pierangli SS, Harris EN. Probing antiphospholipid mediated thrombosis: the interplay between anticardiolipin and endothelial cells. Lupus 2003; 12:539-45.
35. Williams FM, Parmar K, Hughes GR et al. Systemic endothelial cell markers in primary antiphospholipid syndrome. Thromb Haemost 2000; 84:742-6.